Short TSLPR CAR T cells demonstrate activity over a broad dose range and mediate durable eradication of TSLPRhi ALL at high leukemic burden. (A) Dose titration of short TSLPR CAR T cells given on day 3 after high-dose REH TSLPR ALL injection (5 × 10⁶ cells/mouse). ACT, adoptive cell transfer. (B) Survival plot of mice treated in Figure 4A. (C) Flow cytometry of peripheral blood for the presence of CD45⁺ leukemia cells at day 12 after injection. (D) Quantitation of bioluminescence in mice treated in Figure 4A.